相关实验视频
Updated: Sep 19, 2025

08:40
Chronic Salmonella Infection Induced Intestinal Fibrosis
Published on: September 22, 2019
7.3K
炎症性肠道疾病相关的脊椎关节炎的临床特征,病原和治疗方法
Mitsuhiro Akiyama1, Waleed Alshehri1, Koji Suzuki1
1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Autoimmunity reviews
|June 17, 2025
概括
炎症性肠病相关的脊髓关节炎 (IBD-SpA) 影响10-20%的IBD患者. 目前的管理需要综合护理,因为缺乏针对这种复杂疾病的具体指导方针.
科学领域:
- 类风湿病学 类风湿病学
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 炎症性肠病相关的脊髓关节炎 (IBD-SpA) 影响10-20%的炎症性肠病 (IBD) 患者.
- IBD-SpA表现为外周关节炎,轴性干扰和肠炎,缺乏特定的诊断标准或治疗指南.
- 管理目前依赖IBD和脊椎关节炎 (SpA) 的联合建议,需要多学科的合作.
研究的目的:
- 提供IBD-SpA的最新概述,涵盖临床特征,诊断,病原和治疗.
- 突出最近在IBD-SpA.理解和管理方面的进展和未来方向.
- 强调需要量身定制的治疗策略来平衡肠道和关节炎症.
主要方法:
- 关于IBD-SpA的当前文献的审查.
- 分析有关疾病发生的新证据,包括肠道炎症和细胞因子信号通路.
- 评估治疗选择及其对IBD和SPA的影响.
主要成果:
- 亚临床肠道炎症和IL-23-IL-17-TNFα通路与IBD-SpA病变发生有关.
- TNF和JAK抑制剂在IBD和SPA两种疾病中都显示出有效性.
- IL-17 抑制剂可能会加剧肠道炎症,而 vedolizumab 可能会触发 SpA.
结论:
- 由于复杂的病原和治疗考虑,IBD-SpA需要专门的方法.
- 量身定制的治疗策略对于解决胃肠道和关节症状至关重要.
- 需要进一步的研究来制定IBD-SpA的具体指导方针和向治疗方法.
相关概念视频
Inflammatory Bowel Disease II: Crohn's Disease
402
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
402
Inflammatory Bowel Disease I: Ulcerative Colitis
348
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
348
Chronic Bowel Disorders: Introduction
544
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
544
Inflammatory Bowel Disease IV: Pharmacological Management
205
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
205
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
Drugs for Treatment of Ulcerative Colitis in IBD
244
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
244

